A desperate mum has come forward saying that ‘cancer isn’t all about chemo’ and praises a special diet that she believes improved her son's survival chances, increasing them to nearly foolproof ...

INAB READ THE FULL INAB RESEARCH REPORT IN8bio, Inc (NASDAQ:INAB) updates survival data for its INB-100 trial in a February ...

Cancer is one of the greatest healthcare challenges the world currently faces. When it comes to cancer, it is not just the ...

Genomic Interrogation of Secondary-Type Acute Myeloid Leukemia: Response and Outcomes to Contemporary Therapies,” published in the February 2025 issue of American Journal of Hematology by Senapati et ...

The current treatment for relapsed AML, donor lymphocyte infusion (DLI) -- a therapy involving donor immune cells -- has a 5-year survival rate of only 24%, according to research conducted by Pfizer.

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...

IN8bio has announced encouraging new clinical data from its ongoing Phase I trial of INB-100, an allogeneic gamma-delta T ...

IN8bio is accelerating patient enrollment in the INB-100 program and expects to complete enrollment of the expansion cohort in 2025. The company’s FDA discussions confirmed that relapse-free survival ...

All treated AML patients in both the original and expansion cohorts through January 17, 2025 remain in complete remission. The original cohort of AML patients has reached a median CR of 23.3 months, ...

Kura Oncology and Kyowa Kirin reported positive Phase 2 results for ziftomenib in AML and plan Phase 3 trials, with an NDA ...